Somatostatin receptor 1 and 5 double knockout mice mimic neurochemical changes of Huntington's disease transgenic mice

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Rajput, Padmesh S ^a   Kharmate, Geetanjali ^a   Norman, Michael ^b   Liu, Shi He ^b   Sastry, Bhagavatula R ^a   Brunicardi, Charles F ^b   Kumar, Ujendra ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALBINDIN; CALCINEURIN; CALPAIN; CYCLIC AMP; DOPAMINE; ENKEPHALIN; MITOGEN ACTIVATED PROTEIN KINASE 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; NITRIC OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN DARPP 32; PROTEIN KINASE C ALPHA; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 5; SYNAPSIN II; SYNAPSIN IIA; UNCLASSIFIED DRUG; NEURONAL NITRIC OXIDE SYNTHASE; NOS1 PROTEIN, MOUSE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR TYPE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL POPULATION; CONTROLLED STUDY; CORPUS STRIATUM; EXCITOTOXICITY; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; WESTERN BLOTTING; ANIMAL; BRAIN; DISEASE MODEL; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENETICS; METABOLISM; NEOSTRIATUM; NERVE CELL; PATHOLOGY;

MUS; MUS MUSCULUS;

ANIMALS; BRAIN; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; DISEASE MODELS, ANIMAL; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; GENE EXPRESSION REGULATION; GENE KNOCKOUT TECHNIQUES; HUNTINGTON DISEASE; MALE; MICE; MICE, TRANSGENIC; NEOSTRIATUM; NEURONS; NITRIC OXIDE SYNTHASE TYPE I; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, SOMATOSTATIN; SIGNAL TRANSDUCTION;

EID: 80052394262     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024467     Document Type: Article

References (75)

1. de la Monte SM, Vonsattel JP, Richardson EP Jr, (1988) Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J Neuropathol Exp Neurol 47: 516-525.
2. Giampa C, DeMarch Z, D'Angelo V, Morello M, Martorana A, et al. (2006) Striatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions: implications with neuronal vulnerability in Huntington's disease. Eur J Neurosci 23: 11-20.
3. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971-983.
4. Kumar U, Asotra K, Patel SC, Patel YC, (1997) Expression of NMDA Receptor-1 (NR1) and Huntingtin in Striatal Neurons Which Colocalize Somatostatin, Neuropeptide Y, and NADPH Diaphorase: A Double-Label Histochemical and Immunohistochemical Study. Experimental Neurology 145: 412-424.
5. Brinkman RR, Mezei MM, Theilmann J, Almqvist E, Hayden MR, (1997) The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 60: 1202-1210.
6. Gusella JF, MacDonald ME, (2000) Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat Rev Neurosci 1: 109-115.
7. Cicchetti F, Parent A, (1996) Striatal interneurons in Huntington's disease: selective increase in the density of calretinin-immunoreactive medium-sized neurons. Mov Disord 11: 619-626.
8. Ferrante RJ, Kowall NW, Beal MF, Richardson EP Jr, Bird ED, et al. (1985) Selective sparing of a class of striatal neurons in Huntington's disease. Science 230: 561-563.
9. Huang Q, Zhou D, Sapp E, Aizawa H, Ge P, et al. (1995) Quinolinic acid-induced increases in calbindin D28k immunoreactivity in rat striatal neurons in vivo and in vitro mimic the pattern seen in Huntington's disease. Neuroscience 65: 397-407.
10. Kiyama H, Seto-Ohshima A, Emson PC, (1990) Calbindin D28K as a marker for the degeneration of the striatonigral pathway in Huntington's disease. Brain Res 525: 209-214.
11. Sun Z, Wang HB, Deng YP, Lei WL, Xie JP, et al. (2005) Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice. Neurobiol Dis 20: 907-917.
12. Li SH, Li XJ, (2004) Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet 20: 146-154.
13. Albin RL, Young AB, Penney JB, Handelin B, Balfour R, et al. (1990) Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. N Engl J Med 322: 1293-1298.
14. Young AB, Greenamyre JT, Hollingsworth Z, Albin R, D'Amato C, et al. (1988) NMDA receptor losses in putamen from patients with Huntington's disease. Science 241: 981-983.
15. Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH, (1994) Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12: 529-540.
16. Ozawa S, Kamiya H, Tsuzuki K, (1998) Glutamate receptors in the mammalian central nervous system. Prog Neurobiol 54: 581-618.
17. Chen N, Luo T, Wellington C, Metzler M, McCutcheon K, et al. (1999) Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. J Neurochem 72: 1890-1898.
18. Fan MM, Raymond LA, (2007) N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog Neurobiol 81: 272-293.
19. Okamoto S, Pouladi MA, Talantova M, Yao D, Xia P, et al. (2009) Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med 15: 1407-1413.
20. Beal MF, Ferrante RJ, Swartz KJ, Kowall NW, (1991) Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J Neurosci 11: 1649-1659.
21. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, et al. (1986) Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321: 168-171.
22. Aronin N, Cooper PE, Lorenz LJ, Bird ED, Sagar SM, et al. (1983) Somatostatin is increased in the basal ganglia in Huntington disease. Ann Neurol 13: 519-526.
23. Beal MF, Bird ED, Langlais PJ, Martin JB, (1984) Somatostatin is increased in the nucleus accumbens in Huntington's disease. Neurology 34: 663-666.
24. Dawbarn D, De Quidt ME, Emson PC, (1985) Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease. Brain Res 340: 251-260.
25. Nemeroff CB, Youngblood WW, Manberg PJ, Prange AJ Jr, Kizer JS, (1983) Regional brain concentrations of neuropeptides in Huntington's chorea and schizophrenia. Science 221: 972-975.
26. Vincent SR, Johansson O, (1983) Striatal neurons containing both somatostatin- and avian pancreatic polypeptide (APP)-like immunoreactivities and NADPH-diaphorase activity: a light and electron microscopic study. J Comp Neurol 217: 264-270.
27. Patel SC, Papachristou DN, Patel YC, (1991) Quinolinic acid stimulates somatostatin gene expression in cultured rat cortical neurons. J Neurochem 56: 1286-1291.
28. Koh JY, Peters S, Choi DW, (1986) Neurons containing NADPH-diaphorase are selectively resistant to quinolinate toxicity. Science 234: 73-76.
29. Augood SJ, McGowan EM, Emson PC, (1994) Expression of N-methyl-D-aspartate receptor subunit NR1 messenger RNA by identified striatal somatostatin cells. Neuroscience 59: 7-12.
30. Chen Q, Veenman CL, Reiner A, (1996) Cellular expression of ionotropic glutamate receptor subunits on specific striatal neuron types and its implication for striatal vulnerability in glutamate receptor-mediated excitotoxicity. Neuroscience 73: 715-731.
31. Kumar U, (2008) Somatostatin in medium-sized aspiny interneurons of striatum is responsible for their preservation in quinolinic acid and N-methyl-D-asparate-induced neurotoxicity. J Mol Neurosci 35: 345-354.
32. Dawson VL, Kizushi VM, Huang PL, Snyder SH, Dawson TM, (1996) Resistance to neurotoxicity in cortical cultures from neuronal nitric oxide synthase-deficient mice. J Neurosci 16: 2479-2487.
33. Patel YC, (1999) Somatostatin and Its Receptor Family. Frontiers in Neuroendocrinology 20: 157-198.
34. Grant M, Collier B, Kumar U, (2004) Agonist-dependent dissociation of human somatostatin receptor 2 dimers: a role in receptor trafficking. J Biol Chem 279: 36179-36183.
35. Grant M, Patel RC, Kumar U, (2004) The role of subtype-specific ligand binding and the C-tail domain in dimer formation of human somatostatin receptors. J Biol Chem 279: 38636-38643.
36. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, et al. (2000) Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288: 154-157.
37. Pfeiffer M, Koch T, Schroder H, Laugsch M, Hollt V, et al. (2002) Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J Biol Chem 277: 19762-19772.
38. Binaschi A, Bregola G, Simonato M, (2003) On the role of somatostatin in seizure control: clues from the hippocampus. Rev Neurosci 14: 285-301.
39. De Wied D, Sigling HO, (2002) Neuropeptides involved in the pathophysiology of schizophrenia and major depression. Neurotox Res 4: 453-468.
40. Doggrell SA, (2004) The potential of activation of somatostatinergic neurotransmission with FK960 in Alzheimer's disease. Expert Opin Investig Drugs 13: 69-72.
41. Fox L, Alford M, Achim C, Mallory M, Masliah E, (1997) Neurodegeneration of somatostatin-immunoreactive neurons in HIV encephalitis. J Neuropathol Exp Neurol 56: 360-368.
42. Kumar U, (2005) Expression of somatostatin receptor subtypes (SSTR1-5) in Alzheimer's disease brain: An immunohistochemical analysis. Neuroscience 134: 525-538.
43. Bibb JA, Yan Z, Svenningsson P, Snyder GL, Pieribone VA, et al. (2000) Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc Natl Acad Sci U S A 97: 6809-6814.
44. Torres-Peraza J, Pezzi S, Canals JM, Gavalda N, Garcia-Martinez JM, et al. (2007) Mice heterozygous for neurotrophin-3 display enhanced vulnerability to excitotoxicity in the striatum through increased expression of N-methyl-D-aspartate receptors. Neuroscience 144: 462-471.
45. Rajput PS, Billova S, Patel SC, Kharmate G, Somvanshi RK, et al. (2009) Expression of somatostatin and somatostatin receptor subtypes in Apolipoprotein D (ApoD) knockout mouse brain: An immunohistochemical analysis. J Chem Neuroanat 38: 20-33.
46. Ramirez JL, Grant M, Norman M, Wang XP, Moldovan S, et al. (2004) Deficiency of somatostatin (SST) receptor type 5 (SSTR5) is associated with sexually dimorphic changes in the expression of SST and SST receptors in brain and pancreas. Mol Cell Endocrinol 221: 105-119.
47. Hernandez-Espinosa D, Morton AJ, (2006) Calcineurin inhibitors cause an acceleration of the neurological phenotype in a mouse transgenic for the human Huntington's disease mutation. Brain Res Bull 69: 669-679.
48. Cowan CM, Fan MM, Fan J, Shehadeh J, Zhang LY, et al. (2008) Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity. J Neurosci 28: 12725-12735.
49. Fernandes HB, Baimbridge KG, Church J, Hayden MR, Raymond LA, (2007) Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease. J Neurosci 27: 13614-13623.
50. Helyes Z, Pinter E, Sandor K, Elekes K, Banvolgyi A, et al. (2009) Impaired defense mechanism against inflammation, hyperalgesia, and airway hyperreactivity in somatostatin 4 receptor gene-deleted mice. Proc Natl Acad Sci U S A 106: 13088-13093.
51. Viollet C, Vaillend C, Videau C, Bluet-Pajot MT, Ungerer A, et al. (2000) Involvement of sst2 somatostatin receptor in locomotor, exploratory activity and emotional reactivity in mice. Eur J Neurosci 12: 3761-3770.
52. Greengard P, Allen PB, Nairn AC, (1999) Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 23: 435-447.
53. Svenningsson P, Lindskog M, Ledent C, Parmentier M, Greengard P, et al. (2000) Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors. Proc Natl Acad Sci U S A 97: 1856-1860.
54. Baragli A, Alturaihi H, Watt HL, Abdallah A, Kumar U, (2007) Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 Co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell Signal 19: 2304-2316.
55. Rajput PS, Kharmate G, Somvanshi RK, Kumar U, (2009) Colocalization of dopamine receptor subtypes with dopamine and cAMP-regulated phosphoprotein (DARPP-32) in rat brain. Neurosci Res 65: 53-63.
56. Gladding CM, Raymond LA, (2011) Mechanisms underlying NMDA receptor synaptic/extrasynaptic distribution and function. Mol Cell Neurosci.
57. Hardingham GE, (2009) Coupling of the NMDA receptor to neuroprotective and neurodestructive events. Biochem Soc Trans 37: 1147-1160.
58. Hardingham GE, Bading H, (2010) Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci 11: 682-696.
59. Ali NJ, Levine MS, (2006) Changes in expression of N-methyl-D-aspartate receptor subunits occur early in the R6/2 mouse model of Huntington's disease. Dev Neurosci 28: 230-238.
60. Cepeda C, Ariano MA, Calvert CR, Flores-Hernandez J, Chandler SH, et al. (2001) NMDA receptor function in mouse models of Huntington disease. J Neurosci Res 66: 525-539.
61. Milnerwood AJ, Raymond LA, (2010) Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease. Trends Neurosci 33: 513-523.
62. Grant M, Kumar U, (2010) The role of G-proteins in the dimerisation of human somatostatin receptor types 2 and 5. Regul Pept 159: 3-8.
63. Miyakawa T, Leiter LM, Gerber DJ, Gainetdinov RR, Sotnikova TD, et al. (2003) Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc Natl Acad Sci U S A 100: 8987-8992.
64. Blank T, Nijholt I, Teichert U, Kugler H, Behrsing H, et al. (1997) The phosphoprotein DARPP-32 mediates cAMP-dependent potentiation of striatal N-methyl-D-aspartate responses. Proc Natl Acad Sci U S A 94: 14859-14864.
65. Bastia E, Schwarzschild MA, (2003) DARPP chocolate: a caffeinated morsel of striatal signaling. Sci STKE 2003: PE2.
66. Gafni J, Ellerby LM, (2002) Calpain activation in Huntington's disease. J Neurosci 22: 4842-4849.
67. Gafni J, Hermel E, Young JE, Wellington CL, Hayden MR, et al. (2004) Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J Biol Chem 279: 20211-20220.
68. Menalled L, Zanjani H, MacKenzie L, Koppel A, Carpenter E, et al. (2000) Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease. Exp Neurol 162: 328-342.
69. Sun Z, Del Mar N, Meade C, Goldowitz D, Reiner A, (2002) Differential changes in striatal projection neurons in R6/2 transgenic mice for Huntington's disease. Neurobiol Dis 11: 369-385.
70. Lione LA, Carter RJ, Hunt MJ, Bates GP, Morton AJ, et al. (1999) Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J Neurosci 19: 10428-10437.
71. Tallent M, Liapakis G, O'Carroll AM, Lolait SJ, Dichter M, et al. (1996) Somatostatin receptor subtypes SSTR2 and SSTR5 couple negatively to an L-type Ca2+ current in the pituitary cell line AtT-20. Neuroscience 71: 1073-1081.
72. Somvanshi RK, Billova S, Kharmate G, Rajput PS, Kumar U, (2009) C-tail mediated modulation of somatostatin receptor type-4 homo- and heterodimerizations and signaling. Cell Signal 21: 1396-1414.
73. Kumar U, (2007) Colocalization of somatostatin receptor subtypes (SSTR1-5) with somatostatin, NADPH-diaphorase (NADPH-d), and tyrosine hydroxylase in the rat hypothalamus. J Comp Neurol 504: 185-205.
74. Wang XP, Norman MA, Yang J, Cheung A, Moldovan S, et al. (2004) Double-gene ablation of SSTR1 and SSTR5 results in hyperinsulinemia and improved glucose tolerance in mice. Surgery 136: 585-592.
75. Billova S, Galanopoulou AS, Seidah NG, Qiu X, Kumar U, (2007) Immunohistochemical expression and colocalization of somatostatin, carboxypeptidase-E and prohormone convertases 1 and 2 in rat brain. Neuroscience 147: 403-418.